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Regulation of IL-33 Expression by IFN-c and Tumor
Necrosis Factor-a in Normal Human Epidermal
Keratinocytes
Jitlada Meephansan1,3, Hidetoshi Tsuda1,3, Mayumi Komine1,2, Shin-ichi Tominaga2 and Mamitaro Ohtsuki1
IL-33, a member of the IL-1 family, is implicated in type 2 T helper cell immune reactions and acts as an ‘‘alarmin’’
to induce activation of dendritic cells in response to external stimuli. We investigated the effect of inflammatory
cytokines on IL-33 expression in normal human epidermal keratinocytes. IFN-g dose- and time-dependently
induced IL-33 expression in protein and mRNA; this was dependent on extracellular signal–regulated kinase,
p38, EGFR, and JAK phosphorylation. Combined IFN-g and tumor necrosis factor (TNF)-a treatment induced
expression of a 20-kDa band corresponding to mature IL-33, which was abolished by the addition of a calpain
inhibitor. The addition of the inhibitor to IFN-g and TNF-a-stimulated cells also induced strong expression of a
25-kDa band. Small interference (si) RNA for IL-33 abolished expression of the smaller bands and the 30-kDa
IL-33 band, suggesting that these IL-33 forms were IL-33 transcription products. Recombinant IL-33 added in the
medium induced IL-8 production, and RNA knockdown by siRNA enhanced IL-8 expression, suggesting its dual
role as a cytokine and a nuclear factor. These results indicate that IL-33 has a role in inflammatory skin diseases,
in which IFN-g and TNF-a are present in high levels.
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INTRODUCTION
IL-33 is the most recently discovered member of the IL-1
cytokine family and has been identified as a ligand for the IL-1
receptor family member ST2L. Pro-IL-33 is a 30-kDa protein
that is composed of an N-terminal domain and an 18–20-kDa
C-terminal cytokine domain. The 18-kDa C-terminal moiety of
IL-33 is sufficient for binding to the ST2L receptor, which is
expressed on mast cells, eosinophils, several subsets of CD4þ
T cells, and innate immune cells. IL-33 is thought to be a dual-
function protein similar to IL-1a, displaying both nuclear and
extracellular effects (Carriere et al., 2007). IL-33 is constitu-
tively expressed in endothelial cells and in epithelial cells of
tissues exposed to the environment (Moussion et al., 2008),
and can be released in response to tissue injury to rapidly
activate innate immune responses and type 2 T helper cell
(Th-2) immunity. In the nucleus, IL-33 also functions as a
nuclear factor that blocks inflammatory signals, such as NF-kB
(Ali et al., 2011). Several studies have demonstrated that IL-33
expression can be upregulated in vitro in epithelial, mesen-
chymal, and myeloid cells cultured with Toll-like receptor
ligands (Hudson et al., 2008; Nile et al., 2010; Reh et al.,
2010; Shimosato et al., 2010) and proinflammatory stimuli
(Palmer et al., 2009; Prefontaine et al., 2009; Wood et al.,
2009a; Matsuyama et al., 2010). Tumor necrosis factor (TNF)-a
is the ligand used most frequently to induce IL-33 production
by epithelial cells. Few reports have investigated the produc-
tion of IL-33 in epidermal keratinocytes. However, a recent
study demonstrated the upregulation of IL-33 in keratinocytes
and fibroblasts by UVB radiation (Byrne et al., 2011;
Meephansan et al., 2012).
The molecular mechanism underlying pro-IL-33 proces-
sing is poorly understood. Similar to IL-1b and IL-18, IL-33
is considered to be produced intracellularly as pro-IL-33,
cleaved into a mature form, and then released extracellularly
(Schmitz et al., 2005). Caspase-1 and/or caspase-8 are
required for the cleavage of pro-IL-1b and/or pro-IL-18
(Dinarello, 1998; Arend et al., 2008), while calpain is
involved in the cleavage of pro-IL-1a (Dinarello, 1997,
1998; Arend et al., 2008; Maelfait et al., 2008). IL-33 was
initially believed to be cleaved by caspase-1 in the same
manner as pro-IL-1b and pro-IL-18 (Schmitz et al., 2005).
However, several studies have revealed that caspase-1 is not
required for pro-IL-33 release and bioactivity (Cayrol and
Girard, 2009; Luthi et al., 2009; Talabot-Ayer et al., 2009).
It has also been reported that caspase-1, caspase-8, and
calpain are not necessary for the extracellular secretion of
IL-33 (Ohno et al., 2009). One study has suggested that IL-33
maturation is mediated by calpain (Hayakawa et al., 2009).
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We investigated the regulation of IL-33 expression by
inflammatory cytokines, and pro-IL-33 conversion into its
mature form by TNF-a and IFN-g. During the course of
clarifying the enzyme involved in the cleavage of IL-33, we
found a previously unreported 25-kDa form of IL-33.
RESULTS
IFN-c treatment induces IL-33 mRNA and protein
expression in NHEKs
IFN-g has been reported to induce IL-33 expression in airway
smooth muscle cells (Prefontaine et al., 2009). First, we
investigated whether IFN-g induces IL-33 in normal human
epidermal keratinocytes (NHEKs). Real-time PCR (RT-PCR)
revealed that IFN-g significantly increased IL-33 mRNA
expression compared with untreated cells in a dose-
dependent manner (Figure 1a). Western blotting revealed
that there is a constitutive expression of IL-33, and the
intensity of the 30-kDa pro-IL-33 band increased in a dose-
dependent manner at 24 hours after stimulation (data not
shown). The effect of IFN-g on pro-IL-33 expression was also
shown to be time-dependent, starting at 4 hours, persisting for
24 hours, and decreasing back to basal expression levels at
72 hours after IFN-g stimulation (Figure 1b). As shown in
Figure 1c, the 30-kDa pro-IL-33 band was detected only in the
nuclear fraction of the NHEKs. No induction of IL-33 protein
was detected when NHEKs were stimulated with TNF-a. We
used IL-4, a Th-2 cytokine, to stimulate NHEKs. IL-4 also dose-
dependently induced IL-33 (Figure 1d).
Signaling pathways involved in IFN-c-induced IL-33 expression
Previous studies have shown that IFN-g induces the activa-
tion of a variety of signaling pathways (Gough et al., 2008).
To clarify the signal-transduction pathways involved in
IL-33 expression, we used specific inhibitors of intracellular
signaling. IFN-g-induced IL-33 mRNA expression was almost
completely inhibited by PD98059, SB202190, PD153035,
and PD168393, whereas parthenolide and BAY11-7085 were
ineffective (Figure 2a–b). Western blotting mirrored the
RT-PCR results (Figure 2c). In agreement with these findings,
phosphorylation of extracellular signal–regulated kinase
(ERK), p38, and EGFR was detected after exposure of NHEKs
to IFN-g (data not shown).
The JAK–signal transducer and activator of transcription
pathway is strongly induced in cells stimulated with IFN-g.
We used JAK inhibitor I, which inhibits JAK1 and JAK2. JAK
inhibitor I suppressed the induction of IL-33 by IFN-g both at
mRNA and protein levels (Figure 2d–e), indicating that JAKs
were involved in the induction of IL-33.
These results indicate that IFN-g induces IL-33 mRNA and
protein expression through extracellular signal–regulated
kinase, p38, and EGFR-dependent pathways, and that the
JAK–signal transducer and activator of transcription pathway
may be involved in IL-33 induction by IFN-g.
Treatment of NHEKs with TNF-a plus IFN-c induces cleavage
of pro-IL-33 into mature IL-33
TNF-a is a proinflammatory cytokine often found with IFN-g
in inflammatory skin conditions (Prefontaine et al., 2009).
We assessed the effect of TNF-a and IFN-g on the induction
of IL-33 in NHEKs. Interestingly, we found that stimulation
with TNF-a plus IFN-g induced the appearance of a 20-kDa
band, which is considered the mature form of IL-33 and the
result of cleavage of 30-kDa pro-IL-33 (Hayakawa et al.,
2009). This 20-kDa band was broad, ranging from 18 to
22 kDa. The intensity of the 20-kDa band increased in a
dose-dependent manner in response to IFN-g. The 20-kDa
band was not detected at 6 hours after stimulation, but it was
detected at 22 hours after stimulation (Figure 3a).
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Figure 1. IFN-c treatment induces IL-33 mRNA and protein expression in NHEKs. (a) IL-33 mRNA expression analysis by RT-PCR. NHEKs were stimulated with
IFN-g at 0, 10, 20 IUml1 and harvested after 6 hours. (b) NHEKs were harvested at the indicated time points after IFN-g stimulation (100 IUml1); cell lysates
underwent western blotting. (c) Nuclear (N) and cytosolic (C) lysates were analyzed by western blotting after 24-hour NHEK stimulation with TNF-a
(100 ngml1) or IFN-g (100 IUml1). (d) NHEKs were harvested after 24-hour stimulation with IL-4 at the indicated concentrations; cell lysates underwent
western blotting. RT-PCR results are the mean±SD of three independent experiments. Representative western blotting results are shown. *Po0.05, **Po0.01.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NHEKs, normal human epidermal keratinocytes; RT-PCR, real-time PCR; TNF-a, tumor necrosis factor-a.
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We investigated whether IL-33 was secreted into the
culture supernatant. However, we could not detect either
pro-IL-33 or mature IL-33 in supernatants using western
blotting or ELISA (data not shown).
Calpain-mediated cleavage of pro-IL-33
To investigate the candidate enzymes responsible for IL-33
cleavage, we incubated NHEKs with inhibitors of calpain
and/or caspase in the presence of IFN-g and TNF-a; both
calpain and caspase have been reported to be responsible for
cleavage of IL-33. Calpain inhibitors III and IV reduced
expression of the lower part of the broad 20-kDa band, while
caspase inhibitors did not (Figure 3b). Surprisingly, calpain
inhibitors also induced strong expression of a previously
unreported 25-kDa band. Calpain inhibitor III plus caspase
inhibitors produced a similar pattern of bands to calpain
inhibitor III alone, but expression of the upper part of the
broad 20-kDa band was much weaker (data not shown).
To further confirm whether the 20- and 25-kDa bands
were the products of IL-33 transcripts, we used an IL-33 small
interference (si)RNA to suppress IL-33 expression. Transfec-
tion of IL-33 siRNA effectively inhibited pro-IL-33 mRNA
expression, as demonstrated by RT-PCR (Figure 4a). Transfec-
tion of IL-33 siRNA abolished the 20- and 25-kDa bands, as
well as the 30-kDa pro-IL-33 form, as demonstrated by
western blotting (Figure 4b). These findings suggest that the
20- and 25-kDa bands are the products of IL-33 transcripts.
Calpain production is induced by IFN-c and TNF-a in NHEKs
The production of calpain 1 was increased in IFN-g and
TNF-a-treated NHEKs at 24 hours when compared with
untreated or TNF-a-treated cells (Figure 4c). IFN-g-induced
calpain 1 production was consistently observed from 2 to
24 hours (data not shown).
Recombinant IL-33 induced IL-8 production from NHEKs
Next, we investigated whether IL-33 in the medium induced
an inflammatory reaction in NHEKs as an autocrine signal.
Recombinant mature IL-33 added to the medium induced
IL-8 production from NHEKs in a dose- and time-dependent
manner (Figure 5a), which provides evidence that IL-33, as a
cytokine, provokes an inflammatory reaction in NHEKs.
IL-33 knockdown enhanced the induction of IL-8 by
TNF-a in NHEKs
We also investigated the function of IL-33 inside the cells by
suppressing its expression with siRNA. IL-33 in the nucleus
has been reported to function as a nuclear factor repressing
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Figure 2. Signaling molecules involved in IFN-c-induced IL-33 expression. NHEKs were preincubated with inhibitors for (a–c) ERK (50mM PD98059), p38 (5 mM
SB202190), NF-kB (5 mM parthenolide or 2mM BAY11-7085), EGFR (5 mM PD153035 or PD168393), (d, e) JAK (JAK inhibitor I at indicated concentrations) for
1 hour before IFN-g stimulation (100 IUml1) for 8 hours for RT-PCR (a, b, d), and 24 hours for western blotting (c, e). (a, b, d) IL-33 mRNA expression examined
by RT-PCR. Results are the mean±SD of three independent experiments. (c, e) Protein expression of IL-33 examined by western blotting. Loading control:
a-tubulin. *Po0.05, **Po0.01. ERK, extracellular signal–regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NHEKs, normal human
epidermal keratinocytes; RT-PCR, real-time PCR.
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transcription. It has been shown that IL-33 binds to NF-kB
and suppresses its function (Ali et al., 2011). We speculated
that if IL-33 in the nucleus suppressed the function of NF-kB,
IL-33 knockdown would enhance the TNF-a-induced
expression of IL-8 because IL-8 induction by TNF-a occurs
through NF-kB activation (Oliveira et al., 1994). siRNA
successfully suppressed the expression of IL-33 in our
experimental setting (Figure 5b). As expected, TNF-a-induced
expression of IL-8 was enhanced by the knockdown of IL-33
with siRNA both at mRNA and protein levels (Figure 5c–d).
IL-33 is expressed in the nucleus of epidermal keratinocytes
in lichen planus, psoriasis, and atopic dermatitis in vivo
We attempted to detect in vivo expression of IL-33 in the skin
from patients with lichen planus, psoriasis vulgaris, and
atopic dermatitis, the diseases strongly influenced by Th-1,
Th-1 plus Th-17, and Th-2 cytokines, respectively. Skin
samples from these patients exhibited positive staining in the
nuclei of epidermal keratinocytes (Figure 6b–d), while normal
healthy skin exhibited no staining (Figure 6a). In lichen
planus, positive nuclear staining was observed mostly in the
periphery of the lesion rather than in the center. In psoriasis
vulgaris, the staining intensity was variable, but nuclear
staining was observed in the proliferating keratinocytes in the
spinous layer of the lesion. Nuclear staining of epidermal
keratinocytes was also observed in atopic dermatitis, but the
staining was very weak. These results indicate that IL-33
is expressed in the nuclei of epidermal keratinocytes in
inflammatory skin diseases, influenced by IFN-g.
DISCUSSION
IL-33 was first described as a cytokine that mediates Th-2
inflammation (Schmitz et al., 2005). This raises the possibility
of its involvement in allergic skin conditions (contact
hypersensitivity or drug allergy) and Th-2-mediated inflam-
matory skin diseases such as atopic dermatitis, autoimmune
bullous diseases, and skin malignancies. Although little is
known about the regulation of IL-33 expression, the effects of
cytokines vary depending on the cell type in which they are
acting. Our study revealed evidence that IL-33 is constitu-
tively expressed in NHEKs, and that its expression is
upregulated by IFN-g. IFN-g induced IL-33 in a dose- and
time-dependent manner. Increased IL-33 mRNA expression
in response to IFN-g was observed in accordance with an
increase in IL-33 protein expression, detected by western
blotting. However, IL-33 protein was not detected in cell
culture supernatants. Failure to detect secreted endogenous
IL-33 in different types of healthy cells has been reported by
several investigators (Cayrol and Girard, 2009; Luthi et al.,
2009; Matsuyama et al., 2010; Nile et al., 2010); secreted
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IL-33 was only detected in these studies once cells had begun
to undergo necrosis. This suggests that the doses of IFN-g
used in the current experiments may not have been high
enough to induce cell death.
In this study, induction of IL-33 expression by IFN-g was
mediated through activation of the ERK, p38, and EGFR
pathways. IFN-g has been reported to activate EGFR through
transforming growth factor-a production (Matsuura et al.,
1999) and induce CCAAT/enhancer binding protein-b through
activation of EGFR and signal transducer and activator of
transcription-1 in a macrophage cell line (Hu et al., 2001). In
contrast to these studies, our results showed that IFN-g
induced EGFR phosphorylation as early as 30minutes after
stimulation and IL-33 expression as early as 4 hours after
stimulation. This indicates that the effects of IFN-g stimulation
occur too quickly for them to be mediated by transforming
growth factor-a protein expression, and suggests that they
may involve other mechanisms. We also examined the
involvement of the JAK–signal transducer and activator of
transcription pathway, activated in IFN-g-stimulated NHEKs.
JAK inhibitor I, which inhibits JAK1 and JAK2, suppressed the
induction of IL-33 by IFN-g, suggesting that JAK is positively
involved in its induction.
In contrast to previous reports describing the upregulation
of IL-33 by TNF-a in epithelial cell cultures (Palmer et al.,
2009; Prefontaine et al., 2009; Wood et al., 2009a;
Matsuyama et al., 2010), TNF-a did not upregulate IL-33
protein or mRNA expression in NHEKs. To our knowledge it
is previously unreported that combined treatment with IFN-g
and TNF-a dose- and time-dependently induces the appear-
ance of a 20-kDa IL-33 band in addition to a 30-kDa band.
These two bands are products of the IL-33 gene, as treatment
with IL-33 siRNA abolished their expression. This suggests
that IFN-g and TNF-a induce cleavage of pro-IL-33 into
mature IL-33. This finding may characterize the physiological
function of TNF-a in NHEKs.
The 20-kDa IL-33 band, which was initially described by
Schmitz et al. (2005), is believed to be a mature form of IL-33
that is processed by caspase-1. In 2009, Talabot-Ayer et al.
(2009) reported that this 20-kDa band was not produced by
direct caspase-1 cleavage, but mediated by other proteases.
In this study, we clearly demonstrate that expression of
qthe 20-kDa band is suppressed by calpain inhibitor
III (targeting calpains 1 and 2) and calpain inhibitor IV
(targeting calpain 2), but not by caspase inhibitors. This
indicates that calpain is involved in IL-33 maturation in
NHEKs. Our data show, to our knowledge, a previously
unreported involvement of calpain in the cleavage of
naturally produced IL-33 in NHEKs, and correspond well to
an earlier report (Hayakawa et al., 2009). Supporting this
finding, calpain protein was induced by stimulation with
IFN-g plus TNF-a in NHEKs.
To our surprise, the addition of calpain inhibitor to IFN-g
and TNF-a-treated NHEKs generated a strong previously
unreported 25-kDa band. This band was abolished by
treatment with siRNA, suggesting that it is a product of
IL-33 transcripts. We do not know how this 25-kDa band was
generated. However, we speculate that it could be the
product of digestion by unknown enzymes, or the product of
an unknown splice variant of IL-33. These possibilities
require further investigation.
Our study also provides evidence that IL-33 has a role to
play in epidermal keratinocytes. When mature IL-33 is
supplied outside the cells, it functions as a cytokine, inducing
IL-8 in NHEKs. The secretion mechanism of IL-33 from cells
has not been elucidated; however, a recent report suggests
that IL-33 could be secreted from cells stimulated with
mechanical stress (Kakkar et al., 2012). When IL-33 resides in
the nucleus, it functions as a nuclear factor that suppresses
transcription, one possible mechanism of which being
binding to NF-kB. Our results clearly show that IL-33 worked
as a suppressor of IL-8 induction by TNF-a at mRNA and
protein levels. TNF-a has been known to induce IL-8 through
NF-kB (Oliveira et al., 1994), suggesting that IL-33
suppressed IL-8 induction possibly through suppression of
NF-kB function.
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Figure 6. IL-33 is expressed in the nuclei of epidermal keratinocytes in skin samples from patients with atopic dermatitis, lichen planus, and psoriasis.
Formalin-fixed, paraffin-embedded skin samples from three patients with atopic dermatitis and five patients each with lichen planus and psoriasis were retrieved
from the archives of the Department of Dermatology, Jichi Medical University. They were sliced into 4-mm thick sections, autoclaved for 10minutes in citrate
buffer, and immunostained with anti-IL-33 antibody. Representative pictures are shown. (a) Normal control, (b) atopic dermatitis, (c) lichen planus, and
(d) psoriasis. Bar¼ 20mm.
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Immunostaining clearly demonstrated the existence of
IL-33 in vivo. Psoriasis and lichen planus are known to be
strongly influenced by IFN-g; atopic dermatitis less so, which
may explain the staining pattern of our results. The reason the
keratinocytes in the central lesion of lichen planus were not
stained remains unexplained, but it could be because of the
release of intracellular IL-33 into the environment after strong
stimulation, which remains to be clarified.
In summary, we describe the regulation of IL-33 expres-
sion in NHEKs by IFN-g and TNF-a, which stimulate
generation of the 20-kDa mature form of IL-33. This molecule
is produced by calpain cleavage. We also describe the dual
function of IL-33, inducing IL-8 when it works as a cytokine,
suppressing IL-8 induction when it works in the nucleus.
Further investigations should focus on the biological func-
tions of the 20- and 25-kDa IL-33 forms, which may
contribute to the pathogenesis of chronic inflammatory skin
diseases and Th-2 allergic inflammation.
MATERIALS AND METHODS
Cell cultures
NHEKs from neonatal foreskin were purchased from Kurabo (Osaka,
Japan), and cultured in keratinocyte serum-free media (GIBCO,
Invitrogen, Carlsbad, CA) supplemented with 40 mgml-1 of bovine
pituitary extract (Kyokuto Seiyaku, Tokyo, Japan) and 5 ngml-1 of
epidermal growth factor (R&D Systems, Minneapolis, MN).
At approximately 80–90% confluence, cells were trypsinized,
diluted in a ratio of 1:4, and passaged. Cells passaged 3–6 times
were used for this study. Cells were incubated in keratinocyte serum-
free media without bovine pituitary extract and epidermal growth
factor for 24 hours before stimulation. NHEKs were stimulated with
IFN-g and/or TNF-a (R&D Systems), IL-4, or IL-33 (PeproTech, Rocky
Hill, NJ), incubated for the time periods indicated, and harvested for
experiments. Cells were treated with the following signaling
inhibitors at least 30minutes before stimulation: PD98059 (50 mM,
an extracellular signal–regulated kinase pathway inhibitor; Alexis
Biochemicals, Enzo Life Sciences, Farmingdale, NY), SB202190
(5mM, a p38 pathway inhibitor), parthenolide (5 mM, an NF-kB
inhibitor), BAY11-7085 (2mM, an NF-kB inhibitor), PD153035,
PD168393 (5mM, EGFR inhibitors), JAK inhibitor I (at concentrations
indicated in Figure 2, a JAK 1 and 2 inhibitor; Calbiochem, Merck,
Darmstadt, Germany). In some experiments, calpain inhibitor III
(50 mM, a calpain 1 and calpain 2 inhibitor; Calbiochem), calpain
inhibitor IV (50 mM, a calpain 2 inhibitor; Calbiochem), caspase-1
inhibitor I (50 mM, a caspase-1 inhibitor; Calbiochem), caspase-3
inhibitor II (50 mM, a caspase-3, -6, -7, -8, and -10 inhibitor;
Calbiochem), or Z-VAD-FMK (50 mM, a pancaspase inhibitor;
Promega, Tokyo, Japan) were added 1hour before stimulation.
RNA extraction, reverse transcription, and RT-PCR
Total cellular RNA was isolated using ISOGEN (Nippon Gene,
Toyama, Japan) and quantified spectrophotometrically at a wave-
length of 260 nm. Complementary DNA was synthesized from
1–5 mg RNA using a Superscript III First-Strand Kit (Invitrogen)
according to the manufacturer’s protocol. Primers and probes
for human IL-33 (Hs00369211_m1), IL-8 (Hs99999034_m1), and
glyceraldehyde-3-phosphate dehydrogenase were obtained from
Applied Biosystems (Norwalk, CT). RT-PCR was performed on an
Applied Biosystems StepOnePlus Real-Time PCR System (Applied
Biosystems) using the TaqMan RT-PCR Master Mix Reagents Kit
(Applied Biosystems) according to the manufacturer’s directions.
Western blotting
Cells were washed with cold phosphate-buffered saline and
harvested with RIPA buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl,
1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS) containing
a protease inhibitor cocktail (1:100; Roche Applied Science, Tokyo,
Japan) and phosphatase inhibitor (sodium orthovanadate,
100mgml1, 1:200; Sigma-Aldrich, Tokyo, Japan) at the time points
indicated. For separation of nuclear and cytoplasmic components,
up to 2 106 NHEKs were lysed with nuclear and cytosol extraction
buffer containing dithiothreitol and protease inhibitors. Subcellular
fractionation was carried out following the manufacturer’s instruc-
tions (BioVision, Walnut Creek, CA). The concentration of extracted
protein was measured using a BCA Protein Assay Kit (Pierce,
Rockford, IL). Protein (20–40 mg) was resolved by 12.5% SDS-PAGE
and transferred to an Immobilon-P Transfer Membrane (Millipore,
Merck). Membranes were incubated with biotinylated anti-human
IL-33 or anti a-calpain 1 goat polyclonal antibody (36 mgml1,
1:500; R&D Systems, Santa Cruz, Santa Cruz, CA). Detection was
performed using peroxidase-labeled streptavidin (KPL, Gaithersburg,
MD), anti-rabbit IgG horseradish peroxidase-linked secondary anti-
body (Cell Signaling; Life Technologies Japan, Tokyo, Japan), and
peroxidase-labeled anti-mouse secondary antibody (GE Healthcare,
Tokyo, Japan). Alpha-tubulin (Abcam, Tokyo, Japan) was used as an
internal control. Proteins were visualized using an enhanced
chemiluminescence kit (GE Healthcare). Images were captured
using ImageQuant LAS 4000 Version 1.0 (GE Healthcare).
RNA interference
NHEKs were allowed to reach 90% confluence in keratinocyte
serum-free media without bovine pituitary extract or epidermal
growth factor for 24 hours before transfection. Cells were treated
with a mixture of siRNA at a final concentration of 20 nM
(HSS132062, Invitrogen) or negative control (Medium GC Duplex;
Invitrogen), along with 5 ml of lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s instructions. Forty-eight hours after
transfection, cells were starved of epidermal growth factor or bovine
pituitary extract overnight and treated with IFN-g and/or TNF-a and/
or calpain inhibitor III in keratinocyte serum-free media for 24 hours.
ELISA
ELISA for IL-8 in the supernatant was performed using a
Quantikine Human CXCL8/IL-8 ELISA Kit (R&D Systems) according
to manufacturer’s instructions.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue samples from three
cases of atopic dermatitis, five cases of lichen planus, five cases of
psoriasis, and two cases with surrounding normal skin of benign
tumors as normal control were retrieved from the archives of the
Department of Dermatology, Jichi Medical University. Staining was
performed using the avidin-biotin–horseradish peroxidase method
(ABC standard; Vector Laboratories, Burlingame, CA) as previously
described. Antigen retrieval was performed by autoclaving in a
0.01M citrate buffer (pH 6.0) for 10minutes. mAb for human IL-33
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(mouse IgG1k, Nessy-1; Abcam) at a concentration of 1/100 was
used. Color was developed using diaminobenzidine as a substrate.
Slides were examined and images were acquired using a fluores-
cence microscope (BZ8000; KEYENCE, Osaka, Japan).
Statistical analysis
Results were recorded as mean±SD. The Mann–Whitney test was
performed to analyze differences between data obtained from
different experimental groups. All experiments were repeated for at
least three times. A P-value of less than 0.05 was considered
significant.
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